Pharming « Terug naar discussie overzicht

Persbericht Pharming

6 Posts
[verwijderd]
2
Pharming Group N.V. announces:

PHARMING INCLUDED IN NEXT 150 INDEX ON EURONEXT


Leiden, The Netherlands, March 24, 2005. Pharming Group N.V. ("Pharming" or
"the Company") (Euronext: PHARM) (PHAR.AS) announced today that the Company has
been included in the Next 150 Index on the stock exchange of Euronext N.V.
(Euronext).

The Next 150 Index is comprised of mid to large capitalisation stocks on the
Euronext exchange. The index consists of the 150 next largest stocks following
the Euronext 100 index and includes stocks from the Amsterdam, Brussels, Lisbon
and Paris exchanges of Euronext.

"Pharming is pleased to be included in the Next 150 Index as it highlights the
financial performance and progress with its lead product in Phase III clinical
trials," said Dr. Francis Pinto, CEO of Pharming. "The inclusion of Pharming in
the Next 150 Index will further increase awareness of our achievements and
encourage participation of institutional investors."

Pharming will be included in the Euronext Next 150 Index as of April 1st, 2005.
For further information on the Euronext Next 150 Index, please visit
www.euronext.com.

Background on Pharming Group N.V.
Pharming Group N.V. is developing innovative protein therapeutics for unmet
medical needs. The Company's products include potential treatments for genetic
disorders, specialty products for surgical indications, and intermediates for
various applications. Pharming's lead product (recombinant human C1 inhibitor)
for hereditary angioedema is in Phase III of clinical development. The advanced
technologies of the Company include innovative platforms for the production of
protein therapeutics, as well as technology and processes for the purification
and formulation of these products. Additional information is available on the
Pharming website, www.pharming.com.

This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.

End of publication.


gr. Hansio






[verwijderd]
0
Klopt maar nu is het officieel. Is toch weer een flinke stap voorwaarts. Dat zal later blijken.
Zijn de echte jongens die daarin opgenomen worden.
gr. Hansio
[verwijderd]
0
Lijkt me een zeer goede zaak; het betekent vanaf nu serieuze aandacht voor Pharming voor indexbeleggers, grote IBérs, etc. Langzaam bouwt het bedrijf aan een belangrijke positie in de farma sector. Waar zou Pharmingover 2 a 3 jaar staan. Als je je fantasie als belegger de vrije loop laat, kan je nu alvast gaan dromen over.....hetgeen je wenst. Ik ben al dit jaar ermee begonnen. Mooie Paasdagen toegewenst. Gr, Peter
6 Posts
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 17 mei 2024 17:35
Koers 0,845
Verschil -0,014 (-1,63%)
Hoog 0,864
Laag 0,845
Volume 3.070.825
Volume gemiddeld 6.506.215
Volume gisteren 3.675.116

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront